Article
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Journal of viral hepatitis - 1 Apr 2017
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión J A, Gómez A, Devesa M J, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio J M, Rubín A, Salmeron J, Badia E, Planas J M M, Lens S, Turnes J, Montero J L, Buti M, Esteban R, Fernández-Rodríguez C M
Abstract excerpt
Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.